Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: JNJ stock price vs TGT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TGT's multiple
Needs TGT P/E.
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
15 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
Target Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
JNJ vs PFE
Eli Lilly and Company
JNJ vs LLY
Abbott Laboratories
JNJ vs ABT
Amgen Inc.
JNJ vs AMGN
Walmart Inc.
JNJ vs WMT
AMAZON COM INC
JNJ vs AMZN
COSTCO WHOLESALE CORP /NEW
JNJ vs COST
BEST BUY CO INC
JNJ vs BBY
ROSS STORES, INC.
JNJ vs ROST
NORDSTROM INC
JNJ vs JWN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNJ can sustain its superior margins and 6.0% revenue growth while the market continues to award a premium multiple, then hold or accumulate selectively; otherwise, the current price looks stretched because the implied value is 32.8% below the market price and the DCF range is materially lower.
JNJ trades at $263.04 versus an implied P/E-based value of $176.66, implying 32.8% downside on this framework. The gap is driven by JNJ’s much higher earnings quality and profitability than TGT, but the current price still sits above the historical valuation band and well above DCF range.
Supporting Metrics
